COMMUNIQUÉS West-GlobeNewswire
-
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
15/04/2026 -
Sienna Announces April Dividend
15/04/2026 -
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
15/04/2026 -
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
15/04/2026 -
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
15/04/2026 -
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
15/04/2026 -
Inteleos Foundation Announces 2026 MedMissions Award to Advance Maternal Health Ultrasound Access in Five Nations
15/04/2026 -
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
15/04/2026 -
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
15/04/2026 -
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
15/04/2026 -
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
15/04/2026 -
Annual General Meeting of Kuros Biosciences approves all resolutions
15/04/2026 -
Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership
15/04/2026 -
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
15/04/2026 -
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
15/04/2026 -
Cannabis Industry Pioneers Launch grnroom, a Creative Marketing Agency
15/04/2026 -
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
15/04/2026 -
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
15/04/2026 -
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
15/04/2026
Pages